# Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

> **NCT07453602** · PHASE1 · RECRUITING · sponsor: **Arcutis Biotherapeutics, Inc.** · enrollment: 125 (estimated)

## Conditions studied

- Atopic Dermatitis (AD)
- Eczema

## Interventions

- **BIOLOGICAL:** ARQ-234
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07453602
- **Lead sponsor:** Arcutis Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2028-04
- **Final completion:** 2028-04
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07453602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07453602, "Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07453602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*